MarketCap
Facebook
X
Telegram
Matinas BioPharma Holdings Income Statement 2025-2011 | MTNB
Brief overview of revenue and earnings at Matinas BioPharma Holdings
This overview is based on financial performance over the past five years. According to figures from Matinas BioPharma Holdings, revenue changed from $120 thousand to $1.1 million over five years. The cumulative result was +815.2%, corresponding to roughly 55.7% per year. Sales grew at a rate typical of a strong expansion phase.
EBITDA was −14.4 million dollars at the beginning and −23.4 million dollars at the end of the period (−62.1%). The operating result developed less favorably than sales. EBITDA margin moved from −12048.6% to −2133.3%. Higher profitability strengthens the quality of operating growth.
Across the five years, the net result shifted from −14.1 million dollars to −22.9 million dollars. The negative result deepened, showing weaker final efficiency.
The market value of the business moved from $96.1 million to $1.6 million, or −98.3%. Lower capitalization reflects weaker investor expectations.
Summary assessment
The financial trajectory is weak and requires a cautious interpretation. The strongest signals are revenue expansion and higher operating efficiency. Caution is warranted because of lower net income, limited operating profitability and a weaker market valuation. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Matinas BioPharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.74 M | 2.58 M | 1.61 M | 97.6 M | 212 M | 290 M | 200 M | 96.1 M | 104 M | 126 M | 30.9 M | 16 M | - | - | - |
Shares |
5.47 M | 4.87 M | 4.35 M | 217 M | 210 M | 199 M | 145 M | 98.1 M | 90.5 M | 57.7 M | 51.5 M | 32.1 M | - | - | - |
Historical Prices |
0.5 | 0.53 | 0.37 | 0.45 | 1.01 | 1.36 | 2.27 | 0.595 | 1.16 | 1.4 | 0.85 | 0.45 | - | - | - |
Net Income |
-10.3 M | -24.3 M | -22.9 M | -21 M | -23.3 M | -22.4 M | -17.4 M | -14.1 M | -15.5 M | -7.6 M | -9.14 M | -10.2 M | -3.71 M | - | - |
Revenue |
- | - | 1.1 M | 3.19 M | 33 K | 158 K | 89.8 K | 120 K | 150 K | - | 194 K | - | - | - | - |
Gross Profit |
- | - | - | - | - | 158 | - | - | - | - | 194 K | - | - | - | - |
Operating Income |
-6.96 M | -24.6 M | -23.8 M | -24.6 M | -24.7 M | -24.2 M | -18.9 M | -14.6 M | -16.5 M | -8.26 M | -9.91 M | -10.5 M | -3.71 M | - | - |
Interest Expense |
-261 K | 262 K | 340 K | 102 K | 124 K | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-6.93 M | -24.2 M | -23.4 M | -24.3 M | -24.5 M | -23.4 M | -18.1 M | -14.4 M | -16.4 M | -8.2 M | -9.87 M | -10.4 M | -3.71 M | - | - |
Operating Expenses |
- | - | - | - | - | 24.4 M | 19 M | 14.8 M | 16.7 M | 8.26 M | 10.1 M | 10.5 M | - | - | - |
General and Administrative Expenses |
6.88 M | 8.73 M | 10.4 M | 11.1 M | 100 K | 10 M | 7.78 M | 7.98 M | 7.64 M | 4.31 M | 4.81 M | 5.29 M | 1.95 M | - | - |
All numbers in USD currency
Quarterly Income Statement Matinas BioPharma Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
5.09 M | 6.41 M | - | 5.44 M | 5.09 M | 5.09 M | 5.09 M | 5.04 M | 4.99 M | 4.35 M | 4.35 M | 4.35 M | 217 M | 217 M | 217 M | 217 M | 217 M | 217 M | 216 M | 215 M | 205 M | 204 M | 200 M | 199 M | 198 M | 192 M | 163 M | 157 M | 143 M | 117 M | 113 M | 94.7 M | 94 M | 93.5 M | 93.4 M | 92.2 M | 91.6 M | 84.6 M | 58.2 M | 57.6 M | 57.6 M | 57.3 M | 57.2 M | 57 M | 55.9 M | 35.6 M | 32.3 M | 32.1 M | 32 M | 32 M | 32 M | 14.9 M | 10 M | 10 M | - | - | - | - | - | - | - | - |
Net Income |
-5.24 M | -1.92 M | - | -1.53 M | -5.24 M | -1.66 M | - | -4.28 M | -5.72 M | -5.82 M | - | -6.06 M | -6.06 M | -5.51 M | - | -5.46 M | -5.92 M | -5.98 M | - | -6.84 M | -4.79 M | -4.96 M | - | -5.45 M | -5.61 M | -5.05 M | - | -4.4 M | -3.34 M | -4.05 M | - | -2.94 M | -3.41 M | -4.11 M | - | -3.39 M | -3.97 M | -4.5 M | - | -1.84 M | -1.62 M | -2.24 M | - | 7.1 M | 9.1 M | -9.1 M | - | 10.2 M | 10.2 M | -10.2 M | - | -1.46 M | -343 K | -112 K | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | 1.1 M | - | 1.06 M | 1.06 M | - | - | 33.3 K | 33.3 K | 33.3 K | - | 95.8 K | - | - | - | 89.8 K | 89.8 K | - | - | 120 K | 89.8 K | 29.9 K | - | 44.9 K | 44.9 K | 15 K | - | - | - | - | - | 59.9 K | 77 K | 57.6 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-1.84 M | -1.94 M | - | -1.58 M | -1.84 M | -1.95 M | - | -4.38 M | -5.84 M | -5.9 M | - | -6.13 M | -6.16 M | -5.59 M | - | -5.46 M | -5.92 M | -7.72 M | - | -6.88 M | -4.79 M | -6.35 M | - | -5.6 M | -5.77 M | -6.35 M | - | -4.56 M | -4.52 M | -4.1 M | - | -2.95 M | -3.4 M | -4.12 M | - | -3.41 M | -3.98 M | -4.49 M | - | -1.84 M | -1.62 M | -2.24 M | - | -2.16 M | -2.4 M | -2.57 M | - | -2.61 M | -2.42 M | -2.13 M | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-63 K | 15 K | - | 45 K | -63 K | -4 K | - | 106 K | 120 K | 78 K | - | 79 K | 99 K | 73 K | - | 988 | 2 K | 10 K | - | 41.4 K | -1.42 K | - | - | - | 156 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-1.84 M | -1.92 M | - | -1.58 M | -1.82 M | -1.93 M | - | -4.29 M | -5.75 M | -5.81 M | - | -6.04 M | -6.06 M | -5.49 M | - | -5.37 M | -5.84 M | -7.65 M | - | -6.7 M | -4.67 M | -6.29 M | - | -5.43 M | -5.65 M | -6.29 M | - | -4.41 M | -4.42 M | -4.06 M | - | -2.8 M | -3.3 M | -4.07 M | - | -3.35 M | -3.96 M | -4.48 M | - | -1.8 M | -1.61 M | -2.22 M | - | -2.13 M | -2.38 M | -2.56 M | - | -2.55 M | -2.4 M | -2.12 M | - | 662 | 3.58 K | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.45 M | 4.02 M | 4.5 M | - | 1.84 M | 1.62 M | 2.24 M | - | 2.22 M | 2.48 M | 2.63 M | - | 2.61 M | 2.42 M | 2.13 M | - | 1.45 M | 343 K | 112 K | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
1.84 M | 1.94 M | - | 1.58 M | 1.84 M | 1.86 M | - | 2.14 M | 2.47 M | 2.46 M | - | 2.84 M | 2.6 M | 2.71 M | - | 2.82 M | 2.86 M | 2.74 M | - | 29 K | 28 K | 20 K | - | 90 K | 93 K | 80 K | - | 62.1 K | 58.7 K | 117 K | - | 485 K | 342 K | 172 | - | 1.44 M | 1.71 M | 2.12 M | - | 1 M | 978 K | 1.32 M | - | 1.34 M | 1.12 M | 1.18 M | - | 1.54 M | 1.3 M | 1.06 M | - | 708 K | 103 K | 62.5 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Matinas BioPharma Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
Israel
Britain
Singapore
USA
China
Japan
Canada